L-lysine potentiates aminoglycosides against Acinetobacter baumannii via regulation of proton motive force and antibiotics uptake

References

• Greene C, Vadlamudi G, Newton D, et al. The influence of biofilm formation and multidrug resistance on environmental survival of clinical and environmental isolates of Acinetobacter baumannii. Am J Infect Control. 2016;44(5):e65–e71.
   PubMed Web of Science ®Google Scholar
• Demirdal T, Sari US, Nemli SA. Is inhaled colistin beneficial in ventilator associated pneumonia or nosocomial pneumonia caused by Acinetobacter baumannii? Ann Clin Microbiol Antimicrob. 2016;15:11.
   PubMed Web of Science ®Google Scholar
• Ayobami O, Willrich N, Harder T, et al. The incidence and prevalence of hospital-acquired (carbapenem-resistant) Acinetobacter baumannii in Europe, Eastern Mediterranean and Africa: a systematic review and meta-analysis. Emerg Microbes Infect. 2019;8(1):1747–1759.
   PubMedGoogle Scholar
• Domingues S, Rosário N, Cândido Â, et al. Competence for natural transformation is common among clinical strains of resistant Acinetobacter spp. Microorganisms. 2019;7(2).
   Web of Science ®Google Scholar
• Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev. 2008;21(3):538–582.
   PubMed Web of Science ®Google Scholar
• Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol. 2007;5(12):939–951.
   PubMed Web of Science ®Google Scholar
• Perez F, Hujer AM, Hujer KM, et al. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2007;51(10):3471–3484.
   PubMed Web of Science ®Google Scholar
• Giammanco A, Calà C, Fasciana T, et al. Global assessment of the activity of tigecycline against multidrug-resistant gram-negative pathogens between 2004 and 2014 as part of the tigecycline evaluation and surveillance trial. mSphere. 2017;2(1):310–316.
   PubMed Web of Science ®Google Scholar
• Solomon SL, Oliver KB. Antibiotic resistance threats in the United States: stepping back from the brink. Am Fam Physician. 2014;89(12):938–941.
   PubMed Web of Science ®Google Scholar
• Boucher HW, Talbot G, Bradley J, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(1):1–12.
   PubMed Web of Science ®Google Scholar
• Harding CM, Hennon SW, Feldman MF. Uncovering the mechanisms of Acinetobacter baumannii virulence. Nat Rev Microbiol. 2018;16(2):91–102.
   PubMed Web of Science ®Google Scholar
• CDC. Antibiotic resistance threats in the United States, 2019; 2019.
   Google Scholar
• Garneau-Tsodikova S, Labby KJ. Mechanisms of resistance to aminoglycoside antibiotics: overview and perspectives. Medchemcomm. 2016;7(1):11–27.
   PubMed Web of Science ®Google Scholar
• Harms A, Maisonneuve E, Gerdes K. Mechanisms of bacterial persistence during stress and antibiotic exposure. Science. 2016;354(6318):1390–1390.
   Web of Science ®Google Scholar
• Shan Y, Brown Gandt A, Rowe SE, et al. ATP-dependent persister formation in Escherichia coli. mBio. 2017;8(1): e02267-16.
   Web of Science ®Google Scholar
• McKay SL, Portnoy DA. Ribosome hibernation facilitates tolerance of stationary-phase bacteria to aminoglycosides. Antimicrob Agents Chemother. 2015;59(11):6992–6999.
   PubMed Web of Science ®Google Scholar
• Pu Y, Zhao Z, Li Y, et al. Enhanced efflux activity facilitates drug tolerance in dormant bacterial cells. Mol Cell. 2016;62(2):284–294.
   PubMed Web of Science ®Google Scholar
• Taber HW, Mueller JP, Miller PF, et al. Bacterial uptake of aminoglycoside antibiotics. Microbiol Rev. 1987;51(4):439–457.
   PubMedGoogle Scholar
• Hancock RE, Nijnik A, Philpott DJ. Modulating immunity as a therapy for bacterial infections. Nat Rev Microbiol. 2012;10(4):243–254.
   PubMed Web of Science ®Google Scholar
• Lee HH, Collins JJ. Microbial environments confound antibiotic efficacy. Nat Chem Biol. 2011;8(1):6–9.
   PubMed Web of Science ®Google Scholar
• Roemer T, Boone C. Systems-level antimicrobial drug and drug synergy discovery. Nat Chem Biol. 2013;9(4):222–231.
   PubMed Web of Science ®Google Scholar
• Meylan S, Andrews IW, Collins JJ. Targeting antibiotic tolerance, pathogen by pathogen. Cell. 2018;172(6):1228–1238.
   PubMed Web of Science ®Google Scholar
• Dewachter L, Fauvart M, Michiels J. Bacterial heterogeneity and antibiotic survival: understanding and combatting persistence and heteroresistance. Mol Cell. 2019;76(2):255–267.
   PubMed Web of Science ®Google Scholar
• Meylan S, Porter CBM, Yang JH, et al. Carbon sources tune antibiotic susceptibility in Pseudomonas aeruginosa via tricarboxylic acid cycle control. Cell Chem Biol. 2017;24(2):195–206.
   PubMed Web of Science ®Google Scholar
• Allison KR, Brynildsen MP, Collins JJ. Metabolite-enabled eradication of bacterial persisters by aminoglycosides. Nature. 2011;473(7346):216–220.
   PubMed Web of Science ®Google Scholar
• Peng B, Su Y-b, Li H, et al. Exogenous alanine and/or glucose plus kanamycin kills antibiotic-resistant bacteria. Cell Metab. 2015;21(2):249–262.
   PubMed Web of Science ®Google Scholar
• Lebeaux D, Chauhan A, Létoffé S, et al. pH-mediated potentiation of aminoglycosides kills bacterial persisters and eradicates in vivo biofilms. J Infect Dis. 2014;210(9):1357–1366.
   PubMed Web of Science ®Google Scholar
• Zhao L, Jiang J, Zhu Z, et al. Lysine enhances the effect of amphotericin B against Candida albicans in vitro. Acta Biochim Biophys Sin (Shanghai). 2016;48(2):182–193.
   PubMed Web of Science ®Google Scholar
• Lyu Y, Yang X, Goswami S, et al. Amphiphilic tobramycin-lysine conjugates sensitize multidrug resistant gram-negative bacteria to rifampicin and minocycline. J Med Chem. 2017;60(9):3684–3702.
   PubMed Web of Science ®Google Scholar
• Dorr T, Lewis K, Vulic M. SOS response induces persistence to fluoroquinolones in Escherichia coli. PLoS Genet. 2009;5(12):e1000760.
   PubMed Web of Science ®Google Scholar
• Keren I, Kaldalu N, Spoering A, et al. Persister cells and tolerance to antimicrobials. FEMS Microbiol Lett. 2004;230(1):13–18.
   PubMed Web of Science ®Google Scholar
• Chuang YM, Bandyopadhyay N, Rifat D, et al. Deficiency of the novel exopolyphosphatase Rv1026/PPX2 leads to metabolic downshift and altered cell wall permeability in Mycobacterium tuberculosis. MBio. 2015;6(2):e02428.
   PubMed Web of Science ®Google Scholar
• Sun M, Wartel M, Cascales E, et al. Motor-driven intracellular transport powers bacterial gliding motility. Proc Natl Acad Sci USA. 2011;108(18):7559–7564.
   PubMed Web of Science ®Google Scholar
• Yamaguchi A, Ohmori H, Kaneko-Ohdera M, et al. Delta pH-dependent accumulation of tetracycline in Escherichia coli. Antimicrob Agents Chemother. 1991;35(1):53–56.
   PubMed Web of Science ®Google Scholar
• Martinez JL. The antibiotic resistome: challenge and opportunity for therapeutic intervention. Future Med Chem. 2012;4(3):347–359.
   PubMed Web of Science ®Google Scholar
• Lomovskaya O, Bostian KA. Practical applications and feasibility of efflux pump inhibitors in the clinic–a vision for applied use. Biochem Pharmacol. 2006;71(7):910–918.
   PubMed Web of Science ®Google Scholar
• Drawz SM, Bonomo RA. Three decades of beta-lactamase inhibitors. Clin Microbiol Rev. 2010;23(1):160–201.
   PubMed Web of Science ®Google Scholar
• Martinez JL, Rojo F, Vila J. Are nonlethal targets useful for developing novel antimicrobials? Future Microbiol. 2011;6(6):605–607.
   PubMed Web of Science ®Google Scholar
• Foti JJ, Devadoss B, Winkler JA, et al. Oxidation of the guanine nucleotide pool underlies cell death by bactericidal antibiotics. Science. 2012;336(6079):315–319.
   PubMed Web of Science ®Google Scholar
• Kohanski MA, Dwyer DJ, Hayete B, et al. A common mechanism of cellular death induced by bactericidal antibiotics. Cell. 2007;130(5):797–810.
   PubMed Web of Science ®Google Scholar
• Kohanski MA, Dwyer DJ, Wierzbowski J, et al. Mistranslation of membrane proteins and two-component system activation trigger antibiotic-mediated cell death. Cell. 2008;135(4):679–690.
   PubMed Web of Science ®Google Scholar
• Cohen NR, Lobritz MA, Collins JJ. Microbial persistence and the road to drug resistance. Cell Host Microbe. 2013;13(6):632–642.
   PubMed Web of Science ®Google Scholar
• Corona F, Martinez JL. Phenotypic resistance to antibiotics. Antibiotics (Basel). 2013;2(2):237–255.
   PubMedGoogle Scholar
• Drenkard E, Ausubel FM. Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature. 2002;416(6882):740–743.
   PubMed Web of Science ®Google Scholar
• Lewis K. Persister cells. Annu Rev Microbiol. 2010;64:357–372.
   PubMed Web of Science ®Google Scholar
• Lewis K. Persister cells, dormancy and infectious disease. Nat Rev Microbiol. 2007;5(1):48–56.
   PubMed Web of Science ®Google Scholar
• Defraine V, Fauvart M, Michiels J. Fighting bacterial persistence: current and emerging anti-persister strategies and therapeutics. Drug Resist Updat. 2018;38:12–26.
   PubMed Web of Science ®Google Scholar
• Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st century – a clinical super-challenge. N Engl J Med. 2009;360(5):439–443.
   PubMed Web of Science ®Google Scholar
• Cottarel G, Wierzbowski J. Combination drugs, an emerging option for antibacterial therapy. Trends Biotechnol. 2007;25(12):547–555.
   PubMed Web of Science ®Google Scholar
• Pieren M, Tigges M. Adjuvant strategies for potentiation of antibiotics to overcome antimicrobial resistance. Curr Opin Pharmacol. 2012;12(5):551–555.
   PubMed Web of Science ®Google Scholar
• Worthington RJ, Melander C. Combination approaches to combat multidrug-resistant bacteria. Trends Biotechnol. 2013;31(3):177–184.
   PubMed Web of Science ®Google Scholar
• Gilman S, Saunders VA. Accumulation of gentamicin by Staphylococcus aureus: the role of the transmembrane electrical potential. J Antimicrob Chemother. 1986;17(1):37–44.
   PubMed Web of Science ®Google Scholar
• Vila J, Marti S, Sanchez-Cespedes J. Porins, efflux pumps and multidrug resistance in Acinetobacter baumannii. J Antimicrob Chemother. 2007;59(6):1210–1215.
   PubMed Web of Science ®Google Scholar
• Rumbo C, Gato E, López M, et al. Contribution of efflux pumps, porins, and beta-lactamases to multidrug resistance in clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother. 2013;57(11):5247–5257.
   PubMed Web of Science ®Google Scholar
• Ardehali SH, Azimi T, Fallah F, et al. Role of efflux pumps in reduced susceptibility to tigecycline in Acinetobacter baumannii. New Microbes New Infect. 2019;30:100547.
   PubMedGoogle Scholar
• Wang X, Zhao X, Malik M, et al. Contribution of reactive oxygen species to pathways of quinolone-mediated bacterial cell death. J Antimicrob Chemother. 2010;65(3):520–524.
   PubMed Web of Science ®Google Scholar
• Imlay JA. Pathways of oxidative damage. Annu Rev Microbiol. 2003;57:395–418.
   PubMed Web of Science ®Google Scholar
• Brynildsen MP, Winkler JA, Spina CS, et al. Potentiating antibacterial activity by predictably enhancing endogenous microbial ROS production. Nat Biotechnol. 2013;31(2):160–165.
   PubMed Web of Science ®Google Scholar
• Imlay JA, Chin SM, Linn S. Toxic DNA damage by hydrogen peroxide through the Fenton reaction in vivo and in vitro. Science. 1988;240(4852):640–642.
   PubMed Web of Science ®Google Scholar
• Dwyer DJ, Belenky PA, Yang JH, et al. Antibiotics induce redox-related physiological alterations as part of their lethality. Proc Natl Acad Sci USA. 2014;111(20):E2100–9.
   PubMed Web of Science ®Google Scholar
• Belenky P, Ye JD, Porter CBM, et al. Bactericidal antibiotics induce toxic metabolic perturbations that lead to cellular damage. Cell Rep. 2015;13(5):968–980.
   PubMed Web of Science ®Google Scholar
• Rasouly A, Nudler E. Antibiotic killing through oxidized nucleotides. Proc Natl Acad Sci USA. 2018;115(9):1967–1969.
   PubMed Web of Science ®Google Scholar